Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
09
04
2019
revised:
12
07
2019
accepted:
26
07
2019
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer patients, especially when a biomarker of efficacy has been used for patients' selection. In head and neck oncology, cetuximab that targets epidermal growth factor receptor is the only targeted therapy that demonstrated a survival benefit, both in the recurrent and in the locally advanced settings, yet without prior patients' selection. We herein review the clinical development of targeted therapy in head and neck squamous cell carcinoma in light of the molecular landscape and give insights in on how innovative clinical trial designs may speed up biomarker discovery and deployment of new molecular targeted therapies. Given the recent approval of immune checkpoint inhibitors targeting programmed cell death-1 in head and neck squamous cell carcinoma, it remains to be determined how targeted therapy will be incorporated into a global drug development strategy that will inevitably incorporate immunotherapy.
Identifiants
pubmed: 32337482
doi: 10.1093/jncics/pkz055
pii: pkz055
pmc: PMC7049986
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkz055Informations de copyright
© The Author(s) 2019. Published by Oxford University Press.
Références
Lancet Oncol. 2015 Feb;16(2):208-20
pubmed: 25596660
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Oral Oncol. 2016 Oct;61:31-40
pubmed: 27688102
Ann Oncol. 2014 Sep;25(9):1813-20
pubmed: 24928832
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
J Clin Oncol. 2005 Dec 1;23(34):8646-54
pubmed: 16314626
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
JAMA Oncol. 2015 May;1(2):238-44
pubmed: 26181029
Lancet Oncol. 2013 Mar;14(3):257-64
pubmed: 23414589
Cancer Cell. 2004 May;5(5):489-500
pubmed: 15144956
Oncotarget. 2018 Apr 6;9(26):18198-18213
pubmed: 29719599
Oral Oncol. 2013 Aug;49(8):835-41
pubmed: 23727257
Nat Rev Cancer. 2018 Sep;18(9):549-561
pubmed: 29849070
Lancet Oncol. 2015 Feb;16(2):221-32
pubmed: 25596659
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
J Clin Oncol. 2013 Apr 10;31(11):1415-21
pubmed: 23460709
Clin Cancer Res. 2018 Jun 1;24(11):2505-2516
pubmed: 29490986
Lancet Oncol. 2015 Oct;16(13):1324-34
pubmed: 26342236
Oncotarget. 2016 Jul 26;7(30):47418-47430
pubmed: 27329726
Ann Oncol. 2015 Mar;26(3):556-61
pubmed: 25524478
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Res. 2002 Feb 15;62(4):1184-90
pubmed: 11861402
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Clin Cancer Res. 2015 Aug 1;21(15):3377-83
pubmed: 26071484
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
N Engl J Med. 2007 Oct 25;357(17):1695-704
pubmed: 17960012
Ann Oncol. 2017 Sep 1;28(9):2219-2224
pubmed: 28911062
Clin Cancer Res. 2017 May 1;23(9):2186-2194
pubmed: 28151720
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
J Clin Oncol. 2013 Feb 10;31(5):543-50
pubmed: 23295795
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Head Neck. 2016 Dec;38(12):1759-1764
pubmed: 27232378
Oncologist. 2015 Oct;20(10):1119-20
pubmed: 26304911
Clin Cancer Res. 2007 Mar 1;13(5):1552-61
pubmed: 17332301
JAMA Oncol. 2017 Feb 1;3(2):220-226
pubmed: 27930762
J Clin Oncol. 2015 Dec 10;33(35):4202-9
pubmed: 26527790
Otolaryngol Head Neck Surg. 2011 Nov;145(5):767-71
pubmed: 21746839
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Clin Cancer Res. 2014 May 1;20(9):2300-11
pubmed: 24599934
J Clin Oncol. 2009 Mar 1;27(7):1100-7
pubmed: 19171712
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Invest New Drugs. 2016 Aug;34(4):481-9
pubmed: 27225873
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
J Clin Oncol. 2009 Apr 10;27(11):1864-71
pubmed: 19289630
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
Oncogene. 2014 Nov 20;33(47):5442-9
pubmed: 24240680
Cancer Chemother Pharmacol. 2012 Jul;70(1):121-8
pubmed: 22644799
Nature. 2012 Aug 16;488(7411):337-42
pubmed: 22895339
World J Otorhinolaryngol Head Neck Surg. 2016 Jul 19;2(2):68-75
pubmed: 29204550
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
JAMA Oncol. 2017 Feb 1;3(2):244-255
pubmed: 27442865
Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080
pubmed: 18451130
Clin Cancer Res. 2018 Jan 1;24(1):62-72
pubmed: 29061643
Oncotarget. 2017 May 16;8(20):32668-32682
pubmed: 28427242
Lancet Oncol. 2011 Apr;12(4):333-43
pubmed: 21377930
J Clin Oncol. 2004 Jan 1;22(1):77-85
pubmed: 14701768
Chin Clin Oncol. 2014 Jun;3(2):13
pubmed: 25841410
Cancer. 2014 Dec 15;120(24):3940-51
pubmed: 25103371
Br J Cancer. 2011 Aug 23;105(5):618-27
pubmed: 21829197
Lancet Oncol. 2017 Mar;18(3):323-335
pubmed: 28131786
Ann Oncol. 2017 Nov 1;28(11):2827-2835
pubmed: 28950289
Ann Oncol. 2011 May;22(5):1078-87
pubmed: 21048039
Am J Clin Oncol. 2009 Jun;32(3):274-9
pubmed: 19433965
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
JCI Insight. 2017 Mar 23;2(6):e90449
pubmed: 28352657
Genome Res. 2019 Jan;29(1):1-17
pubmed: 30563911
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1192-7
pubmed: 22245208
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Clin Cancer Res. 2015 Feb 15;21(4):870-81
pubmed: 25492084
Ann Oncol. 2010 Apr;21(4):864-70
pubmed: 19850643
Lancet Oncol. 2015 May;16(5):583-94
pubmed: 25892145
N Engl J Med. 2014 Oct 30;371(18):1725-35
pubmed: 25354106
Nat Rev Cancer. 2018 Feb;18(2):89-102
pubmed: 29242642
Ann Oncol. 2014 Jan;25(1):216-25
pubmed: 24256848
Clin Cancer Res. 2011 Sep 1;17(17):5755-64
pubmed: 21750205
Eur J Cancer. 2013 May;49(7):1609-18
pubmed: 23265705
Cancer. 2013 May 15;119(10):1823-31
pubmed: 23408298
Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90
pubmed: 25819749
J Clin Oncol. 2013 Apr 10;31(11):1405-14
pubmed: 23460714
Radiother Oncol. 2011 Jul;100(1):62-9
pubmed: 21821303
J Clin Oncol. 2014 Sep 1;32(25):2735-43
pubmed: 25049329
Ann Oncol. 2012 Aug;23(8):2153-61
pubmed: 22234739
Mol Cancer Ther. 2018 Apr;17(4):795-805
pubmed: 29483208
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Front Oncol. 2016 Oct 31;6:232
pubmed: 27843803
Nat Rev Cancer. 2006 Sep;6(9):714-27
pubmed: 16929325
Clin Cancer Res. 2014 Jun 15;20(12):3289-98
pubmed: 24727329
Curr Opin Oncol. 2016 Sep;28(5):429-36
pubmed: 27366963
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Eur J Cancer. 2018 Mar;91:47-55
pubmed: 29331751
Ann Oncol. 2013 Sep;24(9):2261-6
pubmed: 23704200
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Cancer Discov. 2012 Aug;2(8):694-705
pubmed: 22719020
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Ann Oncol. 2015 Jul;26(7):1476-80
pubmed: 26025965
Oral Oncol. 2015 Apr;51(4):376-82
pubmed: 25593015
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Ann Oncol. 2017 Oct 1;28(10):2533-2538
pubmed: 28961834
J Natl Cancer Inst. 2003 May 7;95(9):646-51
pubmed: 12734315
Ann Oncol. 2018 Apr 1;29(4):985-991
pubmed: 29346507
Oral Oncol. 2016 Jul;58:41-8
pubmed: 27311401
Ann Oncol. 2015 Dec;26(12):2419-28
pubmed: 26371283
Clin Cancer Res. 2007 Dec 1;13(23):7086-92
pubmed: 18056187
Clin Cancer Res. 2018 Jun 15;24(12):2740-2748
pubmed: 29535125
J Clin Oncol. 2003 May 15;21(10):1980-7
pubmed: 12743152
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Lancet. 2000 Mar 18;355(9208):949-55
pubmed: 10768432
Ann Oncol. 2015 Mar;26(3):561-7
pubmed: 25527417
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Cancer Res. 2014 Feb 15;74(4):1091-104
pubmed: 24351288